Pharma
Commented by Fabian Lorenz on May 3rd, 2023 | 07:30 CEST
Starting signal for a share price rally? BioNTech, Bayer, and BioNxt Solutions ahead of important dates
Things can move fast in the biotech sector. The share price of Prometheus Biosciences shot up by a good 75% practically overnight. The reason: US pharmaceutical group Merck & Co wants to buy the Company specializing in treating immune diseases, thus strengthening its own product portfolio. Thanks to clever takeovers, Sartorius has also grown strongly in recent years, become a success story on the German stock market and risen to the DAX. The latest acquisition of the laboratory supplier is Polyplus. The French company develops DNA and RNA components for cell and gene therapies. Is BioNxt, also active in Germany, the next takeover candidate? In any case, the Company is taking big steps towards commercialization. Investors are also hoping for new impetus from Bayer and BioNTech. Both companies have important dates coming up. But analysts are skeptical.
Read
Commented by Armin Schulz on April 24th, 2023 | 08:30 CEST
BioNTech, Defence Therapeutics, Sartorius - Takeover fever in the biotech sector
In the past year, the NASDAQ Biotechnology Index took a severe beating until mid-June. In the meantime, an initial upward trend has developed, and the market is slowly heating up again because some biotech companies are still valued too cheaply. This is when the big players strike, such as Merck & Co, which recently bought Prometheus Biosciences for USD 10.8 billion. The buyer thus paid a premium of a whopping 75% on the previous day's closing price. The biotech start-up Tubulis has also agreed on a collaboration with Bristol-Myers Squibb that could bring more than USD 1 billion into the Munich-based company's coffers. Reason enough to take a look at three companies from the pharmaceutical and biotech sector.
Read
Commented by Stefan Feulner on April 24th, 2023 | 08:20 CEST
The second biotech series is catching up - BioNxt Solutions, Core One Labs, BB Biotech
The months-long correction hit the capital-intensive biotech sector particularly hard. Shares, mainly from the second tier, sometimes had to absorb markdowns of more than three-quarters of their market value and are trading far below their cash holdings. These upheavals are, of course, prompting the big players to acquire new developments at bargain prices and thus significantly increase the value of their portfolios.
Read
Commented by Juliane Zielonka on April 19th, 2023 | 11:20 CEST
BioNxt Solutions, Bayer, Morphosys - Using high-speed technology to beat cancer in men
Cancer drugs dominate the global pharmaceutical market and register a significant share. While the global market was worth around EUR 128.6 billion in 2019, it is expected to be around EUR 159.3 billion in 2022. This is reason enough for pharmaceutical companies such as Bayer and Morphosys to advance their research in these areas. Men are particularly affected by specific types of cancer. But what good is the best therapeutic agent if the effect is not achieved immediately? This is precisely where BioNxt Solutions comes in, with a unique coating technology for the rapid release of active substances.
Read
Commented by Stefan Feulner on April 19th, 2023 | 07:30 CEST
Morphosys, Defence Therapeutics, Moderna - The takeover wave keeps rolling
The biotechnology industry has seen a significant increase in acquisitions and mergers in recent months. Large pharmaceutical companies are looking to expand their portfolios to provide innovative solutions to unmet medical needs. The most recent example is Pfizer's acquisition of Seagen for USD 43 billion. With Big Pharma sitting on filled coffers, this is likely to be just the beginning.
Read
Commented by Juliane Zielonka on April 14th, 2023 | 10:23 CEST
Bayer, Defence Therapeutics, Merck KGaA - Data power ensures high-speed commercialization
Germany is one of the best-funded countries in terms of research-based pharmaceutical companies. Nevertheless, Stefan Oelrich of Bayer Healthcare is critical. He thinks that data protection is putting the brakes on research. Defence Therapeutics, on the other hand, relies on enormous speed. Thanks to their data-driven ACCUM™ platform technology, they are helping mRNA vaccines, in particular, to achieve more intensive results. Pharmaceutical giant Merck is currently experiencing just how valuable data is in the US. In a Phase III clinical trial, the FDA stopped the enrolment of further patients, thus slowing down the research. The reason for the stop, however, is a serious one...
Read
Commented by André Will-Laudien on April 12th, 2023 | 10:34 CEST
Attention, biotech is back! Bayer, Defence Therapeutics, BioNTech - These stocks are breaking out!
For months the market did not care about biotech stocks. But now technical bottoms have been reached, and a rise is likely. In this context, the capital market interest rate is important: if it falls due to increased fears of recession, there is no stopping the biotechs because refinancing costs fall. Sentiment measurements over Easter showed that the risk bias of investors has also returned. If not now, then when, the moment is favorable! Shortlist the following stocks.
Read
Commented by Armin Schulz on April 5th, 2023 | 12:25 CEST
BioNTech, BioNxt Solutions, Bayer - The big one is only a matter of time
The biotech and pharmaceutical industry is currently in a constant state of flux, driven by the introduction of new technologies and the fight against global health problems. Producing medicines and therapies to alleviate diseases is of great value to people's health. Against the backdrop of an ageing population in industrialised nations, the sector will continue to be of great importance. A particular focus is on inventing advanced technologies to fight diseases such as cancer, Alzheimer's and Parkinson's. Today we look at three companies in the biotech and pharma sector.
Read
Commented by Juliane Zielonka on March 30th, 2023 | 12:15 CEST
Saturn Oil + Gas, Bayer, Amazon - Big business on a growth path
The oil industry is booming again: since Russia has been severely sanctioned, EU companies are fleeing to their international production sites to operate cost-efficiently. The winner in the energy poker is Saturn Oil & Gas. The Canadian company is now presenting its results for fiscal year 2022. What is clear is how hard the Company has worked on substance to grow steadily. Change is also felt at Bayer in the wake of the CEO change. Research in the field of women's health is discontinued, only one new blockbuster is still in the pipeline, but it is a big one. The fact that the stock market is associated with fear and greed is shown by the jump in AMC's share price. Just one piece of news from Amazon takeover rumors has investors jumping at the chance.
Read
Commented by Nico Popp on March 27th, 2023 | 09:26 CEST
Cost pressure in the healthcare system - how you benefit: Bayer, BioNxt, BioNTech
What do you think of the German healthcare system? While doctors regularly grumble about bureaucracy and patients about long waiting times or other inconsistencies, a new divide is opening up between pharmaceutical companies. Research-based pharmaceutical companies favour long patent protection, while generics manufacturers want more lax rules. We explain the system and highlight opportunities for investors.
Read